By Counterforce Health Team in Natpara (parathyroid hormone) —

The Requirements Checklist to Get Natpara (Parathyroid Hormone) Covered by Aetna (CVS Health) in California

Quick Answer: Getting Natpara (parathyroid hormone) covered by Aetna (CVS Health) in California requires prior authorization with strict clinical documentation. You'll need confirmed hypoparathyroidism diagnosis, failed calcium/vitamin D therapy records, and endocrinologist support. Important: Takeda discontinued Natpara manufacturing globally in late 2024, with U.S. supply ending December 31, 2025. New patient requests are typically denied due to limited availability. First step: verify current eligibility through Takeda's Special Use Program and gather complete treatment history documentation.

Table of Contents

Who Should Use This Checklist

This guide is for patients with hypoparathyroidism and their healthcare teams seeking Natpara coverage through Aetna (CVS Health) in California. Expected outcome: Due to Natpara's discontinued status, new patient approvals are extremely rare. Existing patients may continue through Takeda's Special Use Program until December 2025.

Key scenarios where this checklist applies:

  • Current Natpara users transferring to Aetna coverage
  • Patients with severe hypocalcemia uncontrolled by standard therapy
  • Appeals for initial denials (though success rates are low for new starts)
Note: Counterforce Health specializes in turning insurance denials into targeted, evidence-backed appeals by analyzing denial letters and plan policies to draft point-by-point rebuttals aligned with payer requirements.

Member & Plan Basics

Coverage Requirements

  • Active Aetna (CVS Health) membership with prescription benefits
  • Prior authorization required for all Natpara requests
  • Specialty pharmacy benefit (typically CVS Specialty)
  • Medical vs. pharmacy benefit: Usually billed under medical benefit using J3590 (unclassified biologics)

Plan Type Considerations

Plan Type Key Requirements Authorization Timeline
Commercial PPO/HMO Standard PA process 14-45 days
Medicare Advantage Expedited available ≤72 hours (urgent)
Medicaid (Medi-Cal) State-specific criteria Varies by county

Clinical Criteria Requirements

Primary Indication

  • Confirmed chronic hypoparathyroidism with appropriate ICD-10 codes:
    • E20.0 (Idiopathic hypoparathyroidism)
    • E20.8 (Other hypoparathyroidism)
    • E20.9 (Hypoparathyroidism, unspecified)
    • E89.2 (Postprocedural hypoparathyroidism)

Laboratory Evidence Required

  • Persistent hypocalcemia documented on ≥2 dates >21 days apart within past year
  • Low or inappropriately normal PTH levels
  • Serum 25-hydroxyvitamin D above lower normal limit
  • Pre-treatment serum calcium >7.5 mg/dL

Failed Standard Therapy

Documentation must show:

  • Calcium supplementation at maximal tolerated doses
  • Active vitamin D analogs (calcitriol, paricalcitol) with specific dosing/duration
  • Clinical failure defined as persistent hypocalcemia, adverse effects, or inability to maintain target calcium levels

Coding & Documentation

Billing Codes

  • HCPCS: J3590 (Unclassified biologics) or C9399 (Unclassified drugs - outpatient)
  • ICD-10: Use appropriate hypoparathyroidism codes listed above
  • NDC: Varies by cartridge strength (verify with CVS Specialty due to discontinued status)

Required Documentation Elements

  • Endocrinologist consultation notes
  • Complete laboratory history (calcium, phosphorus, PTH, vitamin D)
  • Medication trial records with dates, dosages, outcomes
  • Adverse event documentation if applicable

Documentation Packet

Medical Necessity Letter Components

Your endocrinologist's letter must include:

  1. Patient identification and confirmed diagnosis
  2. Treatment history with specific calcium/vitamin D regimens
  3. Failure documentation including:
    • Persistent hypocalcemia despite maximal standard therapy
    • Adverse effects (nephrolithiasis, hypercalciuria, GI intolerance)
    • Quality of life impact
  4. Clinical rationale for Natpara with guideline references
  5. Treatment goals and monitoring plan

Required Attachments

  • Specialist consultation notes
  • Laboratory results (last 30 days)
  • Complete medication history
  • Prior authorization denial letter (if applicable)
  • Takeda Special Use Program enrollment documentation

Submission Process

Forms and Portals

Common Rejection Causes

  • Incomplete laboratory documentation
  • Missing endocrinologist consultation
  • Insufficient evidence of standard therapy failure
  • Outdated forms or missing signatures
Tip: Always obtain confirmation number and track submission status through provider portal.

Specialty Pharmacy Setup

CVS Specialty Transfer Process

  1. Provider initiates: Send prescription to CVS Specialty
    • E-prescribing: NCPDP ID 1466033
    • Fax: 1-800-323-2445
    • Phone: 1-800-237-2767
  2. Patient enrollment: CVS Specialty contacts patient for:
    • Insurance verification
    • Delivery preferences
    • Clinical education
    • Financial assistance coordination
  3. Cold chain requirements: Natpara requires refrigerated shipping (2-8°C) with temperature monitoring

After Submission

Timeline Expectations

  • Initial review: 14-45 days for commercial plans
  • Status checks: Weekly via provider portal
  • Documentation requests: Respond within 5-7 business days

What to Record

  • Confirmation number and submission date
  • Case manager contact information
  • All correspondence and phone call summaries
  • Status update schedule

Common Denial Prevention

Top 5 Pitfalls and Solutions

Common Issue Prevention Strategy
Incomplete lab documentation Submit ≥2 calcium/PTH results >21 days apart
Missing specialist consultation Ensure endocrinologist evaluation within 6 months
Insufficient failure documentation Detail specific dosages, duration, and outcomes of prior therapy
Outdated forms Use current Aetna precertification form with all required fields
Supply availability Verify Takeda Special Use Program enrollment before submission

Appeals Process in California

Internal Appeal (Aetna)

  • Timeline: Must file within 180 days of denial
  • Decision timeframe: 30-45 days (≤72 hours for urgent)
  • Required documents: Original denial letter, additional clinical evidence, peer-reviewed literature

California Independent Medical Review (IMR)

After internal denial, California residents can request IMR through:

Success rates: Approximately 11% of specialty drug denials are overturned in California's workers' compensation system, though commercial plan rates may be higher.

California Advantage: No fee for IMR requests, and decisions are binding on insurers.

When preparing appeals, Counterforce Health helps patients and clinicians by analyzing denial letters and plan policies to create targeted rebuttals with appropriate clinical evidence and guideline citations.

Printable Checklist

Pre-Submission Requirements

  • Confirmed hypoparathyroidism diagnosis with ICD-10 code
  • ≥2 calcium/PTH lab results >21 days apart (last 12 months)
  • Endocrinologist consultation within 6 months
  • Documentation of failed calcium/vitamin D therapy
  • Current Aetna precertification form completed
  • Takeda Special Use Program verification (if applicable)

Submission Steps

  • Submit via Aetna provider portal or approved fax
  • Obtain confirmation number
  • Schedule follow-up for 7-10 days
  • Prepare for potential peer-to-peer review

Post-Decision

  • Review determination letter carefully
  • If approved: coordinate with CVS Specialty for delivery
  • If denied: initiate internal appeal within 180 days
  • Consider California IMR if internal appeal unsuccessful

FAQ

Q: How long does Aetna prior authorization take for Natpara in California? A: Standard commercial plans: 14-45 days. Medicare Advantage urgent requests: ≤72 hours. Medicaid varies by county.

Q: What if Natpara is non-formulary on my Aetna plan? A: Request a formulary exception with medical necessity documentation. Include evidence of failed formulary alternatives.

Q: Can I request expedited review? A: Yes, if clinical urgency exists (risk to life, health, or maximum function recovery). Provide supporting clinical documentation.

Q: Does step therapy apply if I failed treatments outside California? A: Yes, document all prior therapies regardless of location. Include complete medication history with dates and outcomes.

Q: What's the success rate for Natpara appeals in California? A: New patient approvals are rare due to discontinued supply. Existing patients have better success rates for coverage continuation.

Q: How do I transfer from another specialty pharmacy to CVS Specialty? A: Have your prescriber send the prescription directly to CVS Specialty. They'll coordinate prior authorization and cold chain shipping.

Q: Are there alternatives if Natpara is denied? A: Discuss with your endocrinologist: optimized calcium/calcitriol regimens, or consider YORVIPATH (palopegteriparatide) if available.

Q: What financial assistance is available? A: Limited due to discontinued status. Check with patient advocacy organizations and California's prescription assistance programs.

This guide provides general information and should not replace professional medical or legal advice. For specific coverage questions, contact Aetna member services directly. California residents can get free help with insurance disputes through the DMHC Help Center (888-466-2219) or CDI Consumer Hotline (800-927-4357).

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.